DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH NATIONAL HEART, LUNG, AND BLOOD INSTITUTE NHLBI SPECIAL EMPHASIS PANEL ON STRATEGIES TO AUGMENT ALVEOLARIZATION MINUTES OF MEETING SEPTEMBER 29, 1997 The meeting of the Special Emphasis Panel on Strategies to Augment Alveolarization was convened at 9:00 A.M. at the Division of Lung Diseases Conference Room 10029, 6701 Rockledge Drive, Bethesda, MD. In accordance with Public law 92-463, the entire meeting was open to the public. OPEN MEETING I. Call to Order The meeting was called to order by Dr. Merton Bernfield. Dr. Berberich presented the charge to the Panel: The Panel was charged with the following tasks: 1. to identify gaps in our knowledge of the process of alveolarization 2. to clarify the science of retinoic acid (RA) action in the lung 3. to uncover barriers to clinical application 4. to advise NHLBI on best way to stimulate research into this exciting and important area II. Review of Confidentiality and Conflict of Interest Procedures Dr. Berberich informed the Panel members about the requirement to read and sign the conflict of interest statement. All panel members signed the requisite forms. III. Discussion of Proposed Concept Areas The panel's expertise represented the areas of morphogenesis, differentiation, RA metabolism and clinical experience in RA metabolism and chronic lung disease. Brief presentations were made on the following topics relevant to alveolarization: Alveolarization in the Developing Lung; Alveolar Regeneration in the Adult Lung; Role of RA in Limb Development; Administration of Retinols to Premature Babies with Vitamin A Deficiency. Extensive discussion identified areas where additional information is required to better understand alveolarization in the developing and adult lung, in order to assess the opportunities for pharmacological augmentation of alveolarization: 1. Stem cells and markers for septal formation in alveolarization 2. Genes induced by RA for insight into whether remodeling and development utilize the same pathways 3. Activity of other retinoid analogues, agonists, and antagonists on alveolarization 4. Lipid-laden lung fibroblast population in presence and absence of RA 5. RA receptors in emphysema model 6. Characteristics of emphysema in elastase rat models and in adult human smokers 7. Reversibility of RA effect on increased septation 8 Function of newly formed alveoli 9. RA use in prevention as well as repair 10. Other animal models representative of emphysema 11. Tissue levels of RA in premature infants and in adults 12. Dose and pharmacology of RA for potential clinical use 13. Toxicity assessment 14. Quantification of emphysema by CT scan etc. 15. Epidemiology and availability of material from other studies 16. Appropriate measure of outcome for clinical application Recognizing the potential clinical importance of RA administration on alveolarization, NHLBI requested the Special Emphasis Panel (SEP) to determine whether the appropriate steps are being taken to ensure maximal benefit from this emerging area. The discussants acknowledged that since 1992 NHLBI has invested, and continues to invest, in a broad array of both investigator- and institute-initiated projects, directed toward an understanding of the molecular embryology of the lung. The goal of these studies is to unravel the complexity of the integrated network of factors involved in lung development and to apply this knowledge to the development of rational clinical interventions to ensure normal development and to alter disease processes. The effect of RA on alveolarization in both the developing and adult lung suggests that developmental processes may be relevant to repair of the lung following injury. The SEP consensus was that investigations into the above list of topics, in conjunction with the ongoing emphasis on molecular organogenesis and differentiation, would generate important findings into regulation, control, and augmentation of alveolarization in both developing and adult lung. .